Eutectic mixture of local anaesthetics is not effective for extracorporeal shock wave lithotripsy.
Eutectic mixture of local anaesthetics (EMLA) produces cutaneous analgesia. This randomized, double blind, placebo controlled study evaluated the efficacy of EMLA cream during extracorporeal shock wave lithotripsy (ESWL) using the Dornier MFL 5000 lithotripter. Patients scheduled to undergo lithotripsy of renal or pelviureteric junction stones were randomized to receive either 30 g EMLA cream (E) or placebo (P) over the kidney area 60-90 min before the procedure. During lithotripsy all patients received alfentanil via a PCA machine (dose--10 mu.kg-1, lockout time--three minutes, no basal infusion). Additional bolus doses of 5 micrograms.kg-1 alfentanil were administered by the anaesthetist if analgesia was inadequate. Visual analogue scores (VAS) for pain were documented prior to application of the cream. On arrival in the post anaesthesia care unit VAS pain scores were documented for maximum pain and average pain felt during the procedure as well as for satisfaction of the analgesic technique used. Total time spent in the PACU and the Aldrete scores on arrival were compared. Eighty-three patients completed the study. Demographic data were similar between the two groups. Also, VAS for maximal pain, average pain and satisfaction and the total number of shock waves were similar although the EMLA group received more shock waves at the lower energy level (kV) (P < 0.0001). Total dose of alfentanil, dose as boluses, rate of alfentanil use, total number of PCA attempts and missed attempts were similar. The incidence of adverse events such as bradypnoea, airway obstruction, transient hypoxaemia, pruritus and nausea were small and similar. There was a slightly higher incidence of inadequate analgesia documented by the anaesthetist in the EMLA group. There was no difference between the groups with regards to duration of stay in the PACU, incidence of nausea or Aldrete scores on admission to PACU. During lithotripsy EMLA cream does not modify the pain perceived nor does it have any opioid sparing effect. It does not facilitate early discharge from the PACU.